Clinical trial · Interventional
Evaluation of TK3 in Improving Quality of Life in Patients With Malignancy Under Chemotherapy
Assessment of Quality of Life and the Toxicity of Chemotherapy in Patients With Malignancies in Clinical Stages III and IV Under Palliative Treatment With Chemotherapy or Hormone Therapy With or Without Nutritional Supplement TK3
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The association of nutritional supplement TK3 to conventional treatment of cancer patients reduces the intensity and frequency of toxic effects and side effects caused by adjuvant or palliative treatments for the protection of healthy tissues, resulting in a better quality of life.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 1 capsule, 3 times per day | Dietary Supplement | — | UNRESOLVED |
| TK3 | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- interventionNames
- Dietary Supplement: 1 capsule, 3 times per day
- type
- EXPERIMENTAL
- label
- TK3
- description
- 1 capsule, 3 times per day.
- interventionNames
- Dietary Supplement: TK3
Primary outcomes (7)
- measure
- Assessment of Quality of Life
- timeFrame
- 0 day
- description
- Using data from the toxicity of chemotherapy and tolerability of TK3 through the clinical course of patients with malignant CS III and IV with adjuvant or palliative chemotherapy or hormone therapy, associated or not to TK3.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 30 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patient Consent: Informed Consent and informed consent signed and dated by the patient (or his legal representative) and the professional who has obtained the consent. Must be delivered before inclusion. This term must be read and explained to the patient. * Patients female or male, regardless of race or color.Able to ingest oral medication. * Patients 30-80 years, with malignancy, clinical stage III or IV on chemo or hormone therapy. * Patients who have a Karnofsky level between 60 and 80. Exclusion Criteria: * no agreement to sign the Deed of Consent. * Need for use of parenteral nutrition. * The need for food supplement already approved. * Inability to receive the drug orally. * Participation in another clinical trial involving chemotherapy drugs. * Women being sexually active, which does not agree to adhere to the contraceptive methods adopted. * Women lactating * Any problem or condition that the investigator in the trial could be harmful to the patient.
References
Publications (0)
Data not yet available